Clinical Trial Update: A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of enfortumab vedotin in locally advanced or metastatic urothelial cancer has been completed and results have been posted. The update provides the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma
• Urothelial Carcinoma of the Renal Pelvis
• Urothelial Carcinoma of the Ureter
• Urothelial Carcinoma of the Urethra

Drugs mentioned

• Padcev (enfortumab vedotin)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2021-12-17